Evogene Earnings Call: AI Momentum vs. Cash Strain

Evogene Ltd. ((EVGN)) has held its Q1 earnings call. Read on for the main highlights of the call.

Evogene’s latest earnings call mixed upbeat technology milestones with sobering financial realities. Management highlighted momentum in AI-driven discovery and a swelling pharma collaboration pipeline, yet the backdrop was sharply lower revenue, a deeper net loss and a cash position that, while not alarming today, leaves limited room for error without new funding.

AI Platform Push with Google at the Core

Evogene stressed its Campus AI platform as a core asset, underscored by an expanded collaboration with Google announced in February 2026. New AI agents are being integrated to mine scientific literature, build proprietary datasets and refine computational models, aiming to make the company a leader in small‑molecule discovery.

Pharma Collaboration Engine Gains Traction

The pharma division, launched only in early 2025, has quickly assembled a roster of high‑potential partners. In Q1, Evogene added three collaborations targeting neutrophil‑driven inflammation, demyelinating disorders such as MS and chemotherapy resistance, giving it exposure to markets that include a demyelinating disorders opportunity estimated above $26 billion.

AI Validated in Ag Fungicide Program

In agriculture, Evogene’s AgPlenus unit reported striking gains in its Septoria fungicide program using the ChemPass AI engine. Hit rates rose dramatically across iterative screens, from 11 enzymatic hits out of 440 compounds initially to 25 out of 27 in the latest cycle, with biological activity improving in parallel and reinforcing confidence in the AI‑driven discovery loop.

Industry Partners Underscore Technology Credibility

Management pointed to a track record of alliances with leading agriculture players, including prior work with Bayer and Corteva, as proof of industry validation. Alongside numerous biotech and academic ties, these relationships are framed as critical channels for ultimately monetizing Evogene’s discovery capabilities.

Lean Cash Position and Near‑Term Inflows

On the balance sheet, Evogene reported about $13.1 million in cash, cash equivalents and short‑term deposits at March 31, 2026, with quarterly cash usage around $2.8 million. A February warrant inducement brought in roughly $3.4 million in gross proceeds and management expects additional cash from dividend‑style distributions at former subsidiaries, providing some near‑term liquidity support.

Cost Discipline as R&D and Opex Decline

The company emphasized tighter spending, with R&D expenses falling to about $1.8 million from $2.5 million a year earlier, a cut of roughly 28%. Other operating costs also eased as Evogene wound down or sold several non‑core operations, freeing resources for its core technology, pharma and ag‑chem initiatives.

Revenues Collapse as One‑Time Sales Fade

Financial performance on the top line was weak, with Q1 revenue dropping to about $0.3 million from $2.3 million a year earlier, an 87% slide. Management attributed the shortfall mainly to the absence of large, one‑off seat sales booked in 2025, highlighting how current revenue remains lumpy and non‑recurring.

Net Loss Widens on Heavy Financing Charges

The bottom line deteriorated sharply, as net loss nearly doubled to roughly $5.9 million from $3.0 million in the prior‑year quarter. A key driver was a swing from financing income to about $2.7 million in financing expense, largely tied to warrant‑related accounting that produced a one‑time financing charge of approximately $3.8 million.

Bayer Program Ends on Biological Setback

Evogene disclosed that its collaboration with Bayer was terminated after issues with the target protein biology blocked candidate progression, despite the joint work generating novel active compounds. The company framed the outcome as validation of its optimization tools but acknowledged the setback for near‑term agricultural commercialization via that pathway.

Lower Revenue Drives Matching Cost of Sales Drop

Cost of revenues fell from about $1.5 million in Q1 2025 to roughly $0.1 million in Q1 2026, reflecting the steep fall in sales activity. While the decline limits gross margin damage in the short run, it underscores how little commercial scale is currently flowing through Evogene’s platforms.

Portfolio Pruned as Subsidiaries Scaled Back

Strategically, the group has slimmed down, discontinuing or sharply reducing several non‑core subsidiaries and narrowing Costera’s footprint to Brazil. Management argues that this focus will reduce ongoing expenses and concentrate capital on core tech, pharma and ag pipelines, albeit with fewer auxiliary revenue streams.

Runway Risks Without New Capital

With $13.1 million in cash and quarterly usage near $2.8 million, Evogene’s implied runway is roughly four and a half to five quarters at current burn. Management highlighted warrants, subsidiary distributions and future deals as potential offsets, but the numbers signal that additional funding or sizable partnerships will be needed to support multi‑year growth ambitions.

Guidance and Outlook: Progress Promised Amid Funding Needs

Looking ahead, management expects “meaningful progress” across technology, pharma and ag‑chemicals, powered by further AI collaborations, added pharma partners and continued internal pipeline work, including the Septoria program and demyelinating disorder projects. They cautioned that major pharma licensing or equity deals are more likely after near‑term value milestones, leaving investors to weigh strong scientific momentum against thin revenues, ongoing losses and a finite cash runway.

Evogene’s call painted a picture of a company rich in technological promise yet constrained by current financial performance. For investors, the story hinges on whether the expanding collaboration network and validated AI platforms can translate into durable revenues before the balance sheet demands another round of financing.